İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2022 · article

Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients

Dergi EUROPEAN JOURNAL OF RHEUMATOLOGY
ISSN2148-4279
YÖKSİS OpenAlex Açık erişim · diamond TR Index
Yıl2022
Atıf6OpenAlex
Atıf4Semantic Scholar · 1 etkili
Yüzdelik%71,0
FWCI0,821,00 = dünya ortalaması

Veri kaynağı ayrımı

  • YÖKSİSYÖKSİS makale kaydı
  • YÖKSİS dergi adıEUROPEAN JOURNAL OF RHEUMATOLOGY
  • OpenAlexOpenAlex zenginleştirmesi (özet, atıf, konular)
  • Semantic Scholaratıf sayısı (OpenAlex ile birleştirilmez)

Özet

OpenAlex İngilizce

OBJECTIVE: Lung nodules (LNs) impose diagnostic and therapeutic challenges in patients with rheuma- toid arthritis (RA) due to unpredictable outcomes. Potential induction of nodulosis with the use of con- ventional synthetic DMARDs (csDMARD) and lack of knowledge regarding the effect of biologic disease-modifying anti-rheumatic drugs (bDMARDs)/tofacitinib on the LN raise concerns and have an impact on treatment decisions. This study aims to evaluate the possible effects of the bDMARDs/tofa- citinib and csDMARDS on LNs observed in RA patients. METHODS: Electronic health records of RA patients who had LNs detected on computed tomography (CT) between January 2015 and December 2020 were evaluated retrospectively. Patients with follow- up CT images were included in the study. Baseline and follow-up images were meticulously examined for the number, size, attenuation, and cavity formation. Clinical, histopathologic, and laboratory find- ings were analyzed. RESULTS: Forty-two RA patients with LNs were studied, 21 were on bDMARDs/tofacitinib (11 females, mean age: 59.7 6 8.4) and 21 were on csDMARDs (12 females, mean age: 71.4 6 8.3). The proportion of patients with progressed nodules during follow-up was comparable between groups (six patients in bDMARDs/tofacitinib vs seven patients in csDMARDs). Progression of LNs was observed in six patients in the bDMARDs/tofacitinib group: three in anti-TNFa, two in rituximab, and one in abatacept users and none in tofacitinib users. CONCLUSION: Our results suggest that the risk of progression in LNs in RA patients with use of bDMARDs/tofacitinib might not impose a higher risk compared to csDMARDs. Moreover, bDMARDs/ tofacitinib might result in regression in LNs.

Konular

Atıflar

OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.

6atıfOpenAlex · cited_by_count (önbellek / veritabanı)

Yerel katalogda bu makaleye atıf yapan 8 yayın (OpenAlex referans eşleşmesi; tam dünya listesi değildir).

  1. 2025 ACPA is a main risk factor for CT-proven pulmonary nodule progression in patients with rheumatoid arthritisAtıf 2 · OpenAlex
  2. 2025 ACPA is a main risk factor for CT-proven pulmonary nodule progression in patients with rheumatoid arthritisAtıf 2 · OpenAlex
  3. 2025 ACPA is a main risk factor for CT-proven pulmonary nodule progression in patients with rheumatoid arthritisAtıf 2 · OpenAlex
  4. 2025 ACPA is a main risk factor for CT-proven pulmonary nodule progression in patients with rheumatoid arthritisAtıf 2 · OpenAlex
  5. 2025 ACPA is a main risk factor for CT-proven pulmonary nodule progression in patients with rheumatoid arthritisAtıf 2 · OpenAlex
  6. 2025 Radiological and serological predictors of cavitary transformation in rheumatoid arthritis–associated pulmonary nodules: a retrospective cohort studyAtıf 0 · OpenAlex
  7. 2025 Radiological and serological predictors of cavitary transformation in rheumatoid arthritis–associated pulmonary nodules: a retrospective cohort studyAtıf 0 · OpenAlex
  8. 2025 Radiological and serological predictors of cavitary transformation in rheumatoid arthritis–associated pulmonary nodules: a retrospective cohort studyAtıf 0 · OpenAlex

Yazarlar

11
  1. HAZAN KARADENİZ 1
  2. EMETULLAH CİNDİL 2
  3. HAKAN BABAOĞLU 3
  4. ASLIHAN AVANOĞLU GÜLER 4
  5. REYHAN BİLİCİ NECMETTİN ERBAKAN ÜNİVERSİTESİ 5
  6. HASAN SATIŞ 6
  7. NUH ATAŞ 7
  8. BERNA GÖKER GAZİ ÜNİVERSİTESİ 8
  9. ŞEMİNUR HAZNEDAROĞLU 9
  10. MEHMET AKİF ÖZTÜRK 10
  11. ABDURRAHMAN TUFAN 11